BioSpace News Archive

Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today that it will deliver a poster presentation on its lead program, CUE-101, at the Society for Immunotherapy of Cancer 34th Annual Meeting (SITC 2019)

Evaxion Biotech, a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases announced today that it has appointed Glenn S. Vraniak as Chief Financial Officer, effective immediately.

BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a specialty pharmaceutical company dedicated to patients living with chronic conditions, today announced its plans to report its third-quarter 2019 financial results after the close of the U.S. financial markets on Tuesday, November 12, 2019.

Biostage, Inc. (OTCQB: BSTG), a bioengineering company developing next-generation esophageal implants, today announced it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for the Company’s lead product candidate, the Cellspan Esophageal Implant (CEI).

Cellular Biomedicine Group Inc. (NASDAQ: CBMG) (“CBMG” or the “Company”), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced that it will release its financial results for the third quarter ended September 30, 2019 after the market closes on Wednesday, November 6, 2019.

Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVATM (eravacycline for injection) to treat serious and life-threatening infections, today announced that it has entered into a definitive agreement with a healthcare-focused institutional investor

AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, and Juvenescence, a life sciences company developing therapeutics and technologies to treat diseases of aging and to increase human longevity, announce the publication of a new paper in the peer-reviewed scientific journal Regenerative Medicine

Menarini Silicon Biosystems, the pioneer of liquid biopsy and rare cell technologies, will debut the new VRNxT™ volume reduction instrument at the upcoming meeting of the Association for Molecular Pathology (AMP) in Baltimore, November 7-9, 2019.

Calyxt, Inc., a plant-based breeding and technology platform company, will hold a conference call on Wednesday, November 6, 2019 at 4:30 p.m. Eastern time to discuss its results for the third quarter ended September 30, 2019.

Ultragenyx Pharmaceutical Inc. announced that it will host a conference call on Tuesday, November 5, 2019 at 5pm ET to discuss third quarter 2019 financial results and provide a corporate update.